Evidence map›Paper›PMID 36447197›Full record

ArticleBMC pediatrics2022

Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report.

Gianluca Piccolo, Antonio Verrico, Giovanni Morana, Gianluca Piatelli, Patrizia De Marco, Valentina Iurilli, Manila Antonelli, Gabriele Gaggero, Antonia Ramaglia, Marco Crocco and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Gianluca PiccoloDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Università Degli Studi Di Genova, Genoa, Italy.
Antonio VerricoNeuro-Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Giovanni MoranaDepartment of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Turin, Italy.
Gianluca PiatelliNeurosurgery Department, IRCCS Istituto Giannina Gaslini, Via G. Gaslini 5, 16147, Genoa, Italy.
Patrizia De MarcoUOC Medical Genetics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Valentina IurilliPharmacy Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Manila AntonelliDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, University Sapienza, Viale Regina Elena 324, 00161, Rome, Italy.
Gabriele GaggeroPathology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Antonia RamagliaNeuroradiology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Marco CroccoDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Università Degli Studi Di Genova, Genoa, Italy.
Samuele CaruggiDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Università Degli Studi Di Genova, Genoa, Italy.
Claudia MilanaccioNeuro-Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Maria Luisa GarrèNeuro-Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Marco PavanelloNeurosurgery Department, IRCCS Istituto Giannina Gaslini, Via G. Gaslini 5, 16147, Genoa, Italy. pavanellomarco.mp@gmail.com.ORCID 0000-0001-7312-0204
Istituto Giannina Gaslini · ITSapienza University of Rome · ITUniversity of Genoa · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo date, this is the only report showing with close and consecutive magnetic resonance images the extremely rapid response of two types of pediatric low-grade gliomas (PLGG) to vemurafenib and its impact on the surgical approach. CASES PRESENTATION: We report two cases of symptomatic PLGG treated with vemurafenib, a BRAF inhibitor: in a 12-year-old girl it was used as first-line medical treatment, reducing the tumor by 45% within a month and stabilizing to 76% after a year; in a 3-year-old boy with no improvement after SIOP LGG 2004 Protocol, vemurafenib induced in only one week a 34% shrinkage and solved the hydrocephalus, avoiding surgical operation. DISCUSSION AND

conclusionsOur cases demonstrate how an early molecular diagnosis of BRAF mutations through the neurosurgical biopsy is essential to promptly start targeted therapies., whose effect can influence both therapeutic and surgical decisions, hopefully reducing the occurrence of second neurosurgery with associated risks of neurological sequelae.

Indexed as

GliomaProto-Oncogene Proteins B-rafBiopsyChildChild, PreschoolEarly DiagnosisFemaleHumansMaleVemurafenibBRAF protein, humanProto-Oncogene Proteins B-rafVemurafenibBRAFBrain tumorsCase reportNeurosurgeryVemurafenib

Identifiers

PMID36447197
PMCPMC9706968
OpenAlexW4310206592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.